Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001714899-25-000193
Filing Date
2025-11-06
Accepted
2025-11-06 16:05:54
Documents
66
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q dnli-20250930.htm   iXBRL 10-Q 1460812
2 EX-31.1 exhibit311q32025.htm EX-31.1 9896
3 EX-31.2 exhibit312q32025.htm EX-31.2 9916
4 EX-32.1 exhibit321q32025.htm EX-32.1 5559
5 EX-32.2 exhibit322q32025.htm EX-32.2 5688
  Complete submission text file 0001714899-25-000193.txt   6438061

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20250930.xsd EX-101.SCH 43189
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dnli-20250930_cal.xml EX-101.CAL 63661
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20250930_def.xml EX-101.DEF 170826
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20250930_lab.xml EX-101.LAB 577759
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20250930_pre.xml EX-101.PRE 388248
69 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20250930_htm.xml XML 814609
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8547
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38311 | Film No.: 251458188
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)